HC Wainwright reiterated their buy rating on shares of Aethlon Medical (NASDAQ:AEMD – Free Report) in a report released on Thursday,Benzinga reports. They currently have a $7.00 target price on the medical equipment provider’s stock.
Separately, StockNews.com started coverage on Aethlon Medical in a report on Monday, January 27th. They set a “sell” rating for the company.
View Our Latest Report on AEMD
Aethlon Medical Trading Down 4.5 %
About Aethlon Medical
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Further Reading
- Five stocks we like better than Aethlon Medical
- Are Penny Stocks a Good Fit for Your Portfolio?
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- What is the FTSE 100 index?
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- Compound Interest and Why It Matters When Investing
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.